Bioequivalence and Bioavailability Forum

Good morning, all. I'd like to post a follow up on this topic. Hope you don't mind.

Would it be correct to state the following regarding a non-inferiority trial for an ophthalmic drug:

In a non-inferiority trial, the type-I error rate (alpha value, α), represents the consumer’s risk (the risk of concluding in favor of the non-inferiority hypothesis when, in reality, the product is inferior) while the type-II error rate (beta value, β) represents the producer’s risk (the risk of concluding in favor of the hypothesis of inferiority when, in reality, the product is really non-inferior).

What I'm getting at is this. When conducting a non-inferiority trial, are the roles of the type-I and type-II error rate reversed since the null hypothesis and the alternative hypothesis are reversed (Null Hypothesis H0 states non non-inferiority (i.e. inferiority) while Alternative Hypothesis H1 states non-inferiority between Test and Reference products)?

Thank you for any feedback you may have,
The Outlaw Torn